These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 6099388

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes.
    Okamura T, Okunishi H, Ayajiki K, Toda N.
    J Cardiovasc Pharmacol; 1990 Mar; 15(3):353-9. PubMed ID: 1691356
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive mechanism of an angiotensin converting enzyme inhibitor, SA446, in dogs.
    Nishimura K, Okunishi H, Miyazaki M.
    Bull Osaka Med Coll; 1989 Nov; 35(1-2):29-37. PubMed ID: 2486241
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells.
    Lavrentyev EN, Estes AM, Malik KU.
    Circ Res; 2007 Aug 31; 101(5):455-64. PubMed ID: 17626897
    [Abstract] [Full Text] [Related]

  • 5. Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype.
    Hu WY, Fukuda N, Ikeda Y, Suzuki R, Tahira Y, Takagi H, Matsumoto K, Kanmatsuse K, Mugishima H.
    J Cell Physiol; 2003 Aug 31; 196(2):284-92. PubMed ID: 12811821
    [Abstract] [Full Text] [Related]

  • 6. A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).
    Iso T, Yamauchi H, Suda H, Nakata K, Nishimura K, Iwao J.
    Jpn J Pharmacol; 1981 Dec 31; 31(6):875-82. PubMed ID: 6174764
    [Abstract] [Full Text] [Related]

  • 7. Hypotensive effect of SA446, an angiotensin converting enzyme inhibitor, in 2-kidney, 1-clip renal hypertensive and normotensive dogs.
    Nishimura K, Miyazaki M, Okunishi H, Toda N.
    Jpn J Pharmacol; 1987 Apr 31; 43(4):379-87. PubMed ID: 3039218
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril.
    Yamauchi H, Nishimura K, Nakata K, Suda H, Iso T, Shimizu M, Hiramatsu Y.
    Arzneimittelforschung; 1987 Feb 31; 37(2):157-64. PubMed ID: 3034298
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of bestatin on angiotensin I-, II- and III-induced collagen gel contraction in cardiac fibroblasts.
    Lijnen P, Petrov V, Diaz-Araya G, Fagard R.
    J Renin Angiotensin Aldosterone Syst; 2004 Dec 31; 5(4):183-8. PubMed ID: 15803436
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Angiotensin II forming activity of vascular endothelial and smooth muscle cells.
    Ideishi M, Noda K, Sasaguri M, Ikeda M, Arakawa K.
    Artery; 1993 Dec 31; 20(2):95-102. PubMed ID: 8512460
    [Abstract] [Full Text] [Related]

  • 14. Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca2+ channel inhibition in cultured vascular smooth muscle cells.
    Toshiro M, Ueno T, Tanaka M, Oka H, Miyamotq T, Osajima K, Matsumoto K.
    Hypertens Res; 2005 Jun 31; 28(6):545-52. PubMed ID: 16231761
    [Abstract] [Full Text] [Related]

  • 15. Elevated vascular angiotensin converting enzyme in chronic two-kidney, one clip hypertension in the dog.
    Miyazaki M, Okunishi H, Okamura T, Toda N.
    J Hypertens; 1987 Apr 31; 5(2):155-60. PubMed ID: 3038993
    [Abstract] [Full Text] [Related]

  • 16. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells.
    Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M.
    Circ Res; 2005 Sep 02; 97(5):434-42. PubMed ID: 16081869
    [Abstract] [Full Text] [Related]

  • 17. Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum.
    Iwamoto Y, Song K, Takai S, Yamada M, Jin D, Sakaguchi M, Ueda H, Katsuoka Y, Miyazaki M.
    J Pharmacol Exp Ther; 2001 Jul 02; 298(1):43-8. PubMed ID: 11408523
    [Abstract] [Full Text] [Related]

  • 18. Species difference of (2R,4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinec arb oxylic acid (SA446) in inhibition of angiotensin converting enzyme.
    Nakata K, Iwatani T, Horiuchi M, Kito H, Yamauchi H, Iso T.
    Jpn J Pharmacol; 1986 Mar 02; 40(3):367-72. PubMed ID: 3012163
    [Abstract] [Full Text] [Related]

  • 19. Degradation of angiotensin I in the endothelium and smooth muscle of the rat aorta.
    Sim MK.
    Biochem Pharmacol; 1993 Apr 06; 45(7):1524-7. PubMed ID: 8471075
    [Abstract] [Full Text] [Related]

  • 20. Organ selective angiotensin antagonists: sarcosyl1-cysteinyl(S-methyl)8-angiotensin I.
    Freer RJ, Sutherland JC, Day AR.
    Eur J Pharmacol; 1980 Aug 08; 65(4):349-54. PubMed ID: 7408944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.